Proposed Data Collections Submitted for Public Comment and Recommendations, 73588-73589 [2014-29036]
Download as PDF
<![CDATA[
73588
Federal Register / Vol. 79, No. 238 / Thursday, December 11, 2014 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2014–29047 Filed 12–10–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. Written comments should
be received within 60 days of this
notice.
Proposed Data Collections Submitted
for Public Comment and
Recommendations
Proposed Project
Improving the Impact of Laboratory
Practice Guidelines: A New Paradigm
for Metrics—Clinical and Laboratory
Standards Institute—NEW—Center for
Surveillance, Epidemiology and
Laboratory Services (CSELS), Centers for
Disease Control and Prevention (CDC).
The Centers for Disease Control and
Prevention (CDC), as part of its
continuing effort to reduce public
burden, invites the general public and
other Federal agencies to take this
opportunity to comment on proposed
and/or continuing information
collections, as required by the
Paperwork Reduction Act of 1995. To
request more information on the below
proposed project or to obtain a copy of
the information collection plan and
instruments, call 404–639–7570 or send
comments to Leroy A. Richardson, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments submitted in response to
this notice will be summarized and/or
included in the request for Office of
Management and Budget (OMB)
approval. Comments are invited on: (a)
Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
techniques or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
Background and Brief Description
The Centers for Disease Control and
Prevention is funding three 5-year
projects collectively entitled ‘‘Improving
the Impact of Laboratory Practice
Guidelines: A New Paradigm for
Metrics’’. An ‘‘LPG’’ is defined as
written recommendations for voluntary,
standardized approaches for medical
laboratory testing that takes into account
processes for test selection, sample
procurement and processing, analytical
methods, and results reporting for
effective diagnosis and management of
disease and health conditions. LPGs
may be disseminated to, and used by,
laboratorians and clinicians to assist
with test selection and test result
interpretation. The overall purpose of
these cooperative agreements is to
increase the effectiveness of LPGs by
defining measures and collecting
information to inform better LPG
creation, revision, dissemination,
promotion, uptake, and impact on
clinical testing and public health. The
project will explore how these processes
and their impediments and facilitators
differ among various intended users of
LPGs. Through this demonstration
project, CDC seeks to understand how to
customize LPG creation and promotion
to better serve these intended users of
LPGs. An important goal is to help
organizations that sponsor the
development of LPGs create a
sustainable approach for continuous
quality improvement to evaluate and
improve an LPG’s impact through better
collection of information.
The CDC selected three organizations
that currently create and disseminate
LPGs to support activities under a
cooperative agreement funding
mechanism to improve the impact of
their LPGs. The American Society for
Microbiology, the Clinical and
Laboratory Standards Institute (CLSI),
Centers for Disease Control and
Prevention
mstockstill on DSK4VPTVN1PROD with NOTICES
[60Day–15–15GE]
VerDate Sep<11>2014
19:07 Dec 10, 2014
Jkt 235001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
and the College of American
Pathologists, will each use their LPGs as
models to better understand how to
improve uptake and impact of these and
future LPGs. Only the CLSI submission
will be described in this notice.
Specifically, the CLSI project will
address two LPGs that are important to
clinical testing and have a high public
health impact: POCT12, Point-of-Care
Blood Glucose Testing in Acute and
Chronic Care Facilities and POCT13,
Glucose Monitoring in Settings without
Laboratory Support. These LPGs
provide guidance and recommendations
for personnel monitoring patient
glucose levels at sites that have access
to a hospital laboratory as well as
locations, such as physician offices or
nursing homes that do not have an onsite moderate or high complexity
laboratory. It is expected that as a result
of sustained improvements in the
process of creating and updating these
clinical LPGs, public health, which
depends upon accurate and appropriate
laboratory testing guided by the use of
LPGs, will also generally benefit. The
intended users of the CLSI’s POCT12
and POCT13 LPGs will include point-ofcare coordinators, clinical laboratory
directors, medical technologists, nurses,
and medical doctors.
The CLSI plans to collect information
using the same survey instrument,
‘‘Fingerstick Glucose Survey’’ (FGS), on
three separate occasions. During the first
information collection (FGS1), all
targeted respondents will be asked to
complete the survey. Respondents who
indicate that they are not familiar with
either POCT12 or POCT13 will be asked
to provide an email address and offered
a free copy of the applicable LPG. This
subset of respondents will be asked to
complete the same survey (FGS2) 4–6
months after receiving the free LPG.
After analysis of the information
collected during the first two surveys,
CLSI will make improvements to
POCT12 and POCT13, such as provision
of educational materials or helpful
products such as quality control logs,
and may also alter their marketing
campaigns to address issues related to
awareness and use of CLSI documents.
The third survey (FGS3) will then be
sent to all targeted respondents
approximately 2.5 years after the first
survey to obtain information that can be
used to evaluate the impact of these
improvements. Respondents that
received a free copy of POCT12 or
POCT13 following the first survey will
also be contacted by email and asked to
take the third survey.
A link to the survey will be
distributed to all targeted respondents
either by email or postcard. The CLSI
E:\FR\FM\11DEN1.SGM
11DEN1
73589
Federal Register / Vol. 79, No. 238 / Thursday, December 11, 2014 / Notices
will solicit participation from physician
office laboratories, Department of
Defense laboratories, and hospitals that
offer point-of-care glucose testing.
Participants will be recruited by COLA,
the Joint Commission and a Point-ofCare Coordinator network, who have
agreed to distribute links to the survey
through their membership mailing lists.
In addition, participants will also be
solicited through mailing lists
purchased by CLSI from Clinscan and
the American Hospital Association.
Clinical sites offering point-of-care
glucose testing in the Department of
Defense medical system will also be
asked to participate through the
Department of Defense Clinical
Laboratory Improvement Program
(CLIP). In order to obtain the needed
number of respondents for a statistically
valid study, additional laboratories,
selected at random from a database of
Clinical Laboratory Improvement
Amendment (CLIA) certificate holders,
will also be solicited. The survey will
contain instructions to direct it to the
individual in each laboratory
responsible for the development or
The third survey will measure the
impact of the modifications to the
documents and marketing strategy made
based on the data collected from the
first 2 surveys. The response rate for all
surveys will be maximized by repeated
reminders using the same channel that
will be used to distribute the survey. All
targeted laboratories will receive an
email or postcard approximately one
month before distribution of the survey.
This letter will describe the survey and
our purpose for collecting information.
Another email or post card with a link
to the survey will be sent to the same
targeted laboratories. We also plan to
resend the link to the survey to all
targeted laboratories approximately one
month later to remind them of the
survey.
The CLSI believes completion of the
survey will take approximately 15
minutes. The survey will be pilot tested
with 9 or fewer respondents before
deployment to assure that they require
15 minutes or less to take.
There are no costs to respondents
other than their time.
revision of procedures for fingerstick
glucose testing. Directing the survey to
the individual with this specific
responsibility will help to ensure that
only one response will be obtained from
each participating laboratory.
Respondents include point-of-care
coordinators, clinical laboratory
directors, managers, and supervisors,
medical technologists, nurses, and
medical doctors.
The CLSI hopes to achieve an 80%
response rate with their laboratory
information collections, or 24,000 out of
about 30,000 potential respondents. The
second survey will occur approximately
4–6 months after the initial survey and
will only target responders from the first
survey that received a complimentary
copy of one of the LPG documents. CLSI
anticipates that approximately 12,000
participants will be asked to take the
second survey. Approximately two and
a half years after the initial survey, the
same survey will be sent to the same
laboratories as the first survey (i.e. we
will solicit approximately 30,000
potential respondents and expect about
24,000 individuals to take the survey).
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Form name
Point-of-Care Coordinators ....................................................
Laboratory Directors ...............................................................
Laboratory Managers .............................................................
Laboratory Supervisors ..........................................................
Medical Technologists ............................................................
Nurses ....................................................................................
Medical Doctors ......................................................................
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
FGS1
FGS2
FGS3
mstockstill on DSK4VPTVN1PROD with NOTICES
Total ................................................................................
Number of
respondents
Number of
responses per
respondent
500
250
500
4,276
2,138
4,276
4,276
2,138
4,276
4,276
2,138
4,276
7,800
3,900
7,800
5,000
2,500
5,000
3,500
1,750
3,500
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
15/60
125
63
125
1,069
535
1,069
1,069
535
1,069
1,069
535
1,069
1,950
975
1,950
1,250
625
1,250
875
438
875
.....................
........................
........................
........................
18,520
[FR Doc. 2014–29036 Filed 12–10–14; 8:45 am]
BILLING CODE 4163–18–P
19:07 Dec 10, 2014
Jkt 235001
PO 00000
Frm 00048
Total burden
hours
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
VerDate Sep<11>2014
Average
burden per
response
(in hours)
Fmt 4703
Sfmt 9990
E:\FR\FM\11DEN1.SGM
11DEN1
]]>Agencies
[Federal Register Volume 79, Number 238 (Thursday, December 11, 2014)]
[Notices]
[Pages 73588-73589]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-29036]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-15-15GE]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC), as part of
its continuing effort to reduce public burden, invites the general
public and other Federal agencies to take this opportunity to comment
on proposed and/or continuing information collections, as required by
the Paperwork Reduction Act of 1995. To request more information on the
below proposed project or to obtain a copy of the information
collection plan and instruments, call 404-639-7570 or send comments to
Leroy A. Richardson, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or
send an email to omb@cdc.gov.
Comments submitted in response to this notice will be summarized
and/or included in the request for Office of Management and Budget
(OMB) approval. Comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the agency, including whether the information shall
have practical utility; (b) the accuracy of the agency's estimate of
the burden of the proposed collection of information; (c) ways to
enhance the quality, utility, and clarity of the information to be
collected; (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology; and (e)
estimates of capital or start-up costs and costs of operation,
maintenance, and purchase of services to provide information. Burden
means the total time, effort, or financial resources expended by
persons to generate, maintain, retain, disclose or provide information
to or for a Federal agency. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information, to search data sources, to complete and
review the collection of information; and to transmit or otherwise
disclose the information. Written comments should be received within 60
days of this notice.
Proposed Project
Improving the Impact of Laboratory Practice Guidelines: A New
Paradigm for Metrics--Clinical and Laboratory Standards Institute--
NEW--Center for Surveillance, Epidemiology and Laboratory Services
(CSELS), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention is funding three 5-
year projects collectively entitled ``Improving the Impact of
Laboratory Practice Guidelines: A New Paradigm for Metrics''. An
``LPG'' is defined as written recommendations for voluntary,
standardized approaches for medical laboratory testing that takes into
account processes for test selection, sample procurement and
processing, analytical methods, and results reporting for effective
diagnosis and management of disease and health conditions. LPGs may be
disseminated to, and used by, laboratorians and clinicians to assist
with test selection and test result interpretation. The overall purpose
of these cooperative agreements is to increase the effectiveness of
LPGs by defining measures and collecting information to inform better
LPG creation, revision, dissemination, promotion, uptake, and impact on
clinical testing and public health. The project will explore how these
processes and their impediments and facilitators differ among various
intended users of LPGs. Through this demonstration project, CDC seeks
to understand how to customize LPG creation and promotion to better
serve these intended users of LPGs. An important goal is to help
organizations that sponsor the development of LPGs create a sustainable
approach for continuous quality improvement to evaluate and improve an
LPG's impact through better collection of information.
The CDC selected three organizations that currently create and
disseminate LPGs to support activities under a cooperative agreement
funding mechanism to improve the impact of their LPGs. The American
Society for Microbiology, the Clinical and Laboratory Standards
Institute (CLSI), and the College of American Pathologists, will each
use their LPGs as models to better understand how to improve uptake and
impact of these and future LPGs. Only the CLSI submission will be
described in this notice.
Specifically, the CLSI project will address two LPGs that are
important to clinical testing and have a high public health impact:
POCT12, Point-of-Care Blood Glucose Testing in Acute and Chronic Care
Facilities and POCT13, Glucose Monitoring in Settings without
Laboratory Support. These LPGs provide guidance and recommendations for
personnel monitoring patient glucose levels at sites that have access
to a hospital laboratory as well as locations, such as physician
offices or nursing homes that do not have an on-site moderate or high
complexity laboratory. It is expected that as a result of sustained
improvements in the process of creating and updating these clinical
LPGs, public health, which depends upon accurate and appropriate
laboratory testing guided by the use of LPGs, will also generally
benefit. The intended users of the CLSI's POCT12 and POCT13 LPGs will
include point-of-care coordinators, clinical laboratory directors,
medical technologists, nurses, and medical doctors.
The CLSI plans to collect information using the same survey
instrument, ``Fingerstick Glucose Survey'' (FGS), on three separate
occasions. During the first information collection (FGS1), all targeted
respondents will be asked to complete the survey. Respondents who
indicate that they are not familiar with either POCT12 or POCT13 will
be asked to provide an email address and offered a free copy of the
applicable LPG. This subset of respondents will be asked to complete
the same survey (FGS2) 4-6 months after receiving the free LPG. After
analysis of the information collected during the first two surveys,
CLSI will make improvements to POCT12 and POCT13, such as provision of
educational materials or helpful products such as quality control logs,
and may also alter their marketing campaigns to address issues related
to awareness and use of CLSI documents.
The third survey (FGS3) will then be sent to all targeted
respondents approximately 2.5 years after the first survey to obtain
information that can be used to evaluate the impact of these
improvements. Respondents that received a free copy of POCT12 or POCT13
following the first survey will also be contacted by email and asked to
take the third survey.
A link to the survey will be distributed to all targeted
respondents either by email or postcard. The CLSI
[[Page 73589]]
will solicit participation from physician office laboratories,
Department of Defense laboratories, and hospitals that offer point-of-
care glucose testing. Participants will be recruited by COLA, the Joint
Commission and a Point-of-Care Coordinator network, who have agreed to
distribute links to the survey through their membership mailing lists.
In addition, participants will also be solicited through mailing lists
purchased by CLSI from Clinscan and the American Hospital Association.
Clinical sites offering point-of-care glucose testing in the Department
of Defense medical system will also be asked to participate through the
Department of Defense Clinical Laboratory Improvement Program (CLIP).
In order to obtain the needed number of respondents for a statistically
valid study, additional laboratories, selected at random from a
database of Clinical Laboratory Improvement Amendment (CLIA)
certificate holders, will also be solicited. The survey will contain
instructions to direct it to the individual in each laboratory
responsible for the development or revision of procedures for
fingerstick glucose testing. Directing the survey to the individual
with this specific responsibility will help to ensure that only one
response will be obtained from each participating laboratory.
Respondents include point-of-care coordinators, clinical laboratory
directors, managers, and supervisors, medical technologists, nurses,
and medical doctors.
The CLSI hopes to achieve an 80% response rate with their
laboratory information collections, or 24,000 out of about 30,000
potential respondents. The second survey will occur approximately 4-6
months after the initial survey and will only target responders from
the first survey that received a complimentary copy of one of the LPG
documents. CLSI anticipates that approximately 12,000 participants will
be asked to take the second survey. Approximately two and a half years
after the initial survey, the same survey will be sent to the same
laboratories as the first survey (i.e. we will solicit approximately
30,000 potential respondents and expect about 24,000 individuals to
take the survey). The third survey will measure the impact of the
modifications to the documents and marketing strategy made based on the
data collected from the first 2 surveys. The response rate for all
surveys will be maximized by repeated reminders using the same channel
that will be used to distribute the survey. All targeted laboratories
will receive an email or postcard approximately one month before
distribution of the survey. This letter will describe the survey and
our purpose for collecting information. Another email or post card with
a link to the survey will be sent to the same targeted laboratories. We
also plan to resend the link to the survey to all targeted laboratories
approximately one month later to remind them of the survey.
The CLSI believes completion of the survey will take approximately
15 minutes. The survey will be pilot tested with 9 or fewer respondents
before deployment to assure that they require 15 minutes or less to
take.
There are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Point-of-Care Coordinators... FGS1............. 500 1 15/60 125
FGS2............. 250 1 15/60 63
FGS3............. 500 1 15/60 125
Laboratory Directors......... FGS1............. 4,276 1 15/60 1,069
FGS2............. 2,138 1 15/60 535
FGS3............. 4,276 1 15/60 1,069
Laboratory Managers.......... FGS1............. 4,276 1 15/60 1,069
FGS2............. 2,138 1 15/60 535
FGS3............. 4,276 1 15/60 1,069
Laboratory Supervisors....... FGS1............. 4,276 1 15/60 1,069
FGS2............. 2,138 1 15/60 535
FGS3............. 4,276 1 15/60 1,069
Medical Technologists........ FGS1............. 7,800 1 15/60 1,950
FGS2............. 3,900 1 15/60 975
FGS3............. 7,800 1 15/60 1,950
Nurses....................... FGS1............. 5,000 1 15/60 1,250
FGS2............. 2,500 1 15/60 625
FGS3............. 5,000 1 15/60 1,250
Medical Doctors.............. FGS1............. 3,500 1 15/60 875
FGS2............. 1,750 1 15/60 438
FGS3............. 3,500 1 15/60 875
---------------
Total.................... ................. .............. .............. .............. 18,520
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-29036 Filed 12-10-14; 8:45 am]
BILLING CODE 4163-18-P
